BridgeBio Pharma, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
BBIO Company Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
BBIO Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BBIO Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of BBIO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BBIO's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of BBIO in WallStreetBets Daily Discussion
BBIO News
Recent insights relating to BBIO
CNBC Recommendations
Recent picks made for BBIO stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BBIO
Corporate Flights
Flights by private jets registered to BBIO
Our Analysis